

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
24 October 2024 (24.10.2024)



(10) International Publication Number  
**WO 2024/216346 A1**

(51) International Patent Classification:

*C12N 15/90* (2006.01) *A61P 35/00* (2006.01)  
*A61K 35/17* (2015.01) *C12N 5/0783* (2010.01)  
*A61K 39/00* (2006.01) *C12N 15/11* (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/AU2024/050379

(22) International Filing Date:

19 April 2024 (19.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2023901180 20 April 2023 (20.04.2023) AU

(71) Applicant: **PETER MACCALLUM CANCER INSTITUTE** [AU/AU]; 305 Grattan Street, Melbourne, Victoria 3000 (AU).

(72) Inventors: **BEAVIS, Paul**; 3/170 Spring Street, Reservoir, Victoria 3073 (AU). **YAP, Kah Min**; 551 Swanston Street, Carlton, Victoria 3053 (AU). **CHEN, Xi Ying Amanda**; Unit W1406, 105 Batman Street, West Melbourne, Victoria 3003 (AU). **DARCY, Phillip K.**; 18 Goulburn Grove, Yalambie, Victoria 3085 (AU).

(74) Agent: **DAVIES COLLISON CAVE PTY LTD**; 1 Nicholson Street, Melbourne, Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - II

(57) Abstract: The present disclosure provides an engineered T cell comprising a heterologous nucleotide sequence encoding at least one immunomodulatory factor, wherein the heterologous nucleotide sequence is introduced in-frame of an endogenous gene of the T cell, wherein expression of the endogenous gene is under the control of endogenous regulatory elements, wherein expression of the heterologous nucleotide sequence is controlled by the endogenous regulatory elements of the endogenous gene, and wherein the endogenous gene is selected from the group consisting of *RGS16*, *RGS1*, *RGS2*, and *CLU*. In some embodiments, there is provided pharmaceutical compositions comprising the engineered T cell disclosed herein, and methods for the treatment of cancer using the engineered T cell disclosed herein. The present disclosure also provides genome editing systems, and methods for enhancing the function of a T cell using the genome editing systems disclosed herein.



WO 2024/216346 A1